Addition of 2-deoxyglucose enhances growth inhibition but reverses acidification in colon cancer cells treated with phenformin

Anticancer Research

Volumn 31, Issue 2, 2011, Pages 421-426

  Lea, Michael A ^a   Chacko, Jerel ^a   Bolikal, Sandhya ^a   Hong, Ji Y ^a   Chung, Ryan ^a   Ortega, Andres ^a   DesBordes, Charles ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

2 deoxyglucose; Acidification; Colon cancer; Metformin; Phenformin

Indexed keywords

ALKALINE PHOSPHATASE; BUTYRIC ACID; DEOXYGLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PHENFORMIN;

ACIDIFICATION; ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PH; CELL PROLIFERATION; CELL STRAIN CACO 2; COLON CANCER; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADENYLATE KINASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUTYRATES; CACO-2 CELLS; CELL GROWTH PROCESSES; COLONIC NEOPLASMS; DEOXYGLUCOSE; DRUG SYNERGISM; ENZYME ACTIVATION; ENZYME INDUCTION; HT29 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; PHENFORMIN;

EID: 79953236410     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Peng L, Li Z-R, Green RS, Holzman IR and Lin J: Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139: 1619-1625, 2009.
2. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel, Giogetti-Peraldi, Cormont M, Bertolotto C, Deckert M, Auberger P, Tanti J-F and Bost F: Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70: 2465-2475, 2010.
3. Ben Sahra I, Le Marchand-Brustel Y, Tanti J-F and Bost F: Metformin in cancer therapy: a new perspective for an old diabetic drug. Mol Cancer Ther 9(5): 1092-1099, 2010.
4. Zhang L, He HM and Balschi JA: Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration. Am J Physiol Heart Circ Physiol 293: H457-H466, 2007. (Pubitemid 47105103)
5. Caraci F, Chisari M, Frasca G, Chiecio S, Salomone S, Pinto A, Sortino MA and Bianchi A: Effects of phenformin on the proliferation of human tumor cell lines. Life Sci 74: 643-650, 2003. (Pubitemid 37423999)
6. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber, Fujii N, Musi N, Hirshman MF, Goodyear LJ and Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174, 2001. (Pubitemid 32995375)
7. Lea MA, Shareef A, Sura M and desBordes C: Induction of histone acetylation and inhibition of growth by phenyl alkanoic acids and structurally related molecules. Cancer Chemother Pharmacol 54: 57-63, 2004. (Pubitemid 38858366)
8. Lea MA, Ibeh C, Shah N and Moyer MP: Induction of differentiation of colon cancer cells by combined inhibition of kinases and histone deacetylase. Anticancer Res 27: 741-748, 2007. (Pubitemid 46586976)
9. Hu G-X, Chen G-R, Xu H, Ge R-S and Lin J: Activation of the AMP-activated protein kinase by short-chain fatty acids is the main mechanism underlying the beneficial effect of a high fiber-diet on the metabolic syndrome. Med Hypotheses 74: 123-126, 2010.
10. Bando K, Ochiai S, Kunimatsu T, Deguchi J, Kimura J, Funabashi H and Seki T: Comparison of potential risks of lactic acidosis induction by biguanides in rats. Regulat Toxicol Pharmacol 58: 155-160, 2010.
11. Cayley WE: Does metformin increase the risk of fatal or nonfatal lactic acidosis? Am Family Physician 82: 1068-1070, 2010.
12. Wills BK, Byant SM, Buckley P and Seo B: Can acute overdose of metformin lead to lactic acidosis? Am J Emerg Med 28: 857-861, 2010.
13. Scarlett D-JG, Herst PM and Berridge MV: Multiple proteins with single activities or a single protein with multiple activities: The conundrum of cell surface NADH oxidoreductases. Biochim Biophys Acta 1708: 108-119, 2005. (Pubitemid 40798535)
14. Elisia I, Popovich DG and Kitts DD: Evaluation of viability assays for anthocyanins in cultured cells. Phytochem Anal 19: 479-486, 2008.
15. Jaszczyszyn A and Gasiorowski K: limitations of the MTT assay in cell viability testing. Adv Clin Exp Med 17: 525-529, 2008.
16. Bodmer M, Meier C, Krahenbuhl S, Jick SS and Meier CR: Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33: 1304-1308, 2010.
17. DeCensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennan A, Bonanni B and Gandini S: Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 3: 1451-1461, 2010.
18. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, Koide T, Tokoro C, Abe Y, Inamori M, Nakagama H and Nakajima A: Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res 3: 1077-1083, 2010.
19. Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, Nozaki Y, Yoneda K, Fujita K, Yoneda M, Inamori M, Tomatsu A, Chihara T, Shimpo K, Nakagama H and Nakajima A: Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinogen 49: 662-671, 2010.
20. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AKL, Gans ROB and De Vries EGE: Metformin: Taking away the candy for cancer? Europ J Cancer 46: 2369-2380, 2010.
21. Martin-Castillo B, Vazquez-Martin A, Oliverase-Ferraros C and Menendez JA: Metformin and cancer. Doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 9: 1057-1064, 2010.
22. Pollak M: Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res 3: 1060-1065, 2010.
23. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B and Thompson CB: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752, 2007. (Pubitemid 47105521)